文献速递炎症性肠病

储袋炎及储袋克罗恩样病变预防与治疗的药物治疗:系统评价与Meta分析

Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Gastroenterol · 2024-10-16

该系统评价与Meta分析评估了益生菌、抗生素、5-氨基水杨酸类、非全身性口服糖皮质激素及先进疗法对储袋炎和储袋克罗恩样病变(CLDP)的预防与治疗效果。益生菌对储袋炎的一级和二级预防均有效,抗生素治疗急性和慢性储袋炎有效,先进疗法治疗慢性抗生素难治性储袋炎和CLDP有效。鉴于数据总体质量较低,需进一步研究确认这些发现。

要点

  • 益生菌对储袋炎一级预防(RR 0.18)和二级预防(RR 0.17)均有效。
  • 抗生素治疗急性和慢性储袋炎有效(RR 1.67),环丙沙星和甲硝唑方案优于利福昔明。
  • 先进疗法治疗慢性抗生素难治性储袋炎(RR 1.71)和CLDP(RR 2.49)有效,不同类别间无显著差异。

核心结论

  • 多种药物干预对储袋炎和CLDP的预防和治疗有效。
  • 鉴于数据总体质量较低,需进一步研究确认这些发现。

研究设计与样本

  • 通过系统文献综述,识别评估益生菌、抗生素、5-氨基水杨酸类、非全身性口服糖皮质激素及先进疗法预防和治疗储袋炎和CLDP效果的研究进行Meta分析。
  • 主要结局为储袋炎预防的储袋炎发生率和储袋炎及CLDP治疗的临床应答。
  • 使用现有安慰剂应答率或从储袋炎、溃疡性结肠炎和克罗恩病临床试验得出的假设自发改善率估计相对有效性。

主要发现

  • 益生菌对储袋炎一级预防有效(RR 0.18;95%CI 0.05-0.62)。
  • 益生菌对储袋炎二级预防有效(RR 0.17;95%CI 0.09-0.34)。
  • 抗生素治疗急性和慢性储袋炎有效(12个队列;RR 1.67;95%CI 1.34-2.01;应答率65%;95%CI 52-75),环丙沙星和甲硝唑为基础的方案比利福昔明更有效。
  • 先进疗法治疗慢性抗生素难治性储袋炎有效(31个队列;RR 1.71;95%CI 1.28-2.56;应答率50%;95%CI 43-57)。
  • 先进疗法治疗CLDP有效(10个队列;RR 2.49;95%CI 1.87-3.73;应答率74%;95%CI 68-79),不同类别间无显著差异。

关键数值与推荐

  • 益生菌预防储袋炎:一级预防RR 0.18(95%CI 0.05-0.62),二级预防RR 0.17(95%CI 0.09-0.34)。
  • 抗生素治疗急性和慢性储袋炎:12个队列,RR 1.67(95%CI 1.34-2.01),应答率65%(95%CI 52-75)。
  • 先进疗法治疗慢性抗生素难治性储袋炎:31个队列,RR 1.71(95%CI 1.28-2.56),应答率50%(95%CI 43-57)。
  • 先进疗法治疗CLDP:10个队列,RR 2.49(95%CI 1.87-3.73),应答率74%(95%CI 68-79)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 数据总体质量较低。
  • 需进一步研究确认这些发现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Pouchitis and Crohn's-like disease of the pouch (CLDP) are common in patients who undergo ileal pouch anal anastomosis for ulcerative colitis. We conducted separate systematic reviews to evaluate the effectiveness of available interventions to prevent and treat pouchitis and CLDP. METHODS: Through systematic literature reviews, we identified studies that evaluated the effectiveness of probiotics, antibiotics, 5-aminosalicylates, nonsystemic oral corticosteroids, and advanced therapies for prevention and treatment of pouchitis and CLDP for meta-analysis. Primary outcomes were occurrence of pouchitis for pouchitis prevention and clinical response for pouchitis and CLDP treatment. We estimated the relative effectiveness of these interventions using the existing placebo response rates or hypothetical spontaneous improvement rates derived from clinical trials of pouchitis, ulcerative colitis, and Crohn's disease. RESULTS: Probiotics were effective for primary (relative risk [RR] 0.18; 95% confidence interval [CI] 0.05-0.62) and secondary prevention (RR 0.17; 95% CI 0.09-0.34) of pouchitis. Antibiotics were effective for treatment of acute and chronic pouchitis (12 cohorts; RR 1.67; 95% CI 1.34-2.01; response rate 65%; 95% CI 52-75) with ciprofloxacin and metronidazole-based regimens being more effective than rifaximin. Advanced therapies were effective for treatment of chronic antibiotic-refractory pouchitis (31 cohorts; RR 1.71; 95% CI 1.28-2.56; response rate 50%; 95% CI 43-57) and CLDP (10 cohorts; RR 2.49; 95% CI 1.87-3.73; response rate 74%; 95% CI 68-79) without significant difference between classes. DISCUSSION: Multiple medical interventions are effective for prevention and treatment of pouchitis and CLDP. Given the overall low quality of data, further research is needed to confirm these findings.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Syal G, Barnes E, Raffals L, et al. Medical Therapies for Prevention and Treatment of Inflammatory Pouch Disorders-A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2024. PMID: 39466277. doi:10.14309/ajg.0000000000003136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。